Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Advaxis, Inc. (ADXS) To Present At SITC Cancer Immunotherapy Clinical Trials Workshop

|Includes: Advaxis Inc. (ADXS)

Advaxis, a leading developer of the next generation of immunotherapies for cancer and infectious diseases, announced today that an abstract has been accepted for oral presentation at The Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Clinical Trials: Concepts and Challenges workshop being held next week at the National Institutes of Health Campus (Masur Auditorium) in Bethesda, MD.

The abstract titled "Early Therapeutic Cancer Vaccine Clinical Trial Development" will be presented on April 4 at 10:30 am during Session 1 by Dr. Robert Petit, VP of Clinical Development and Medical Affairs at Advaxis. Dr. Petit will describe Advaxis' experience with conducting early clinical trials with therapeutic Lm-LLO immunotherapies.

"The selection of our abstract for presentation at SITC provides an opportunity for Advaxis to share our experience in introducing Lm-LLO immunotherapy in a global clinical trial setting where there is great medical need," stated Dr. Petit. "We are working toward a future when immunotherapy can fully take its place alongside conventional treatments in the global battle against cancer."

For more information, visit

Please see disclaimer on the QualityStocks website: